Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates

The Journal of Pharmacology and Experimental Therapeutics
Brian D KangasJack Bergman

Abstract

The primary psychoactive ingredient of marijuana, Δ(9)-tetrahydrocannabinol (Δ(9)-THC), has medicinal value but also produces unwanted deleterious effects on cognitive function, promoting the search for improved cannabinergic therapeutics. The present studies used a battery of touchscreen procedures in squirrel monkeys to compare the effects of different types of cannabinergic drugs on several measures of performance including learning (repeated acquisition), cognitive flexibility (discrimination reversal), short-term memory (delayed matching-to-sample), attention (psychomotor vigilance), and motivation (progressive ratio). Drugs studied included the cannabinoid agonist Δ(9)-THC, fatty acid amide hydrolase (FAAH) inhibitor cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester (URB597), and endocannabinoid anandamide and its stable synthetic analog methanandamide [(R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide]. The effects of Δ(9)-THC and anandamide after treatment with the cannabinoid receptor type 1 inverse agonist/antagonist rimonabant [5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1Hpyrazole-3-carboxamide] and the FAAH inhibitor URB597, respectively, also were examined. The results showed the follow...Continue Reading

References

Jan 1, 1992·Behavioral and Neural Biology·H EichenbaumN J Cohen
Apr 1, 1968·Canadian Journal of Psychology·N J MackintoshV Vanderver
Jun 19, 1998·Psychopharmacology·M R Weed, L H Gold
Jun 3, 1999·Psychopharmacology·C M Williams, T C Kirkham
Apr 26, 2000·Behavioural Pharmacology·P J WinsauerJ M Moerschbaecher
Dec 4, 2002·Nature Medicine·Satish KathuriaDaniele Piomelli
Jul 5, 2003·Physiological Reviews·Tamas F FreundDaniele Piomelli
Apr 1, 1959·Journal of the Experimental Analysis of Behavior·D S BLOUGH
Jan 22, 2005·Current Opinion in Pharmacology·Leslie Iversen
Apr 1, 2006·Neuroscience and Biobehavioral Reviews·Alice EgertonJudith A Pratt
Oct 5, 2006·Psychopharmacology·Mohini Ranganathan, Deepak Cyril D'Souza
Sep 2, 2008·Neurobiology of Aging·Alan H NagaharaMark H Tuszynski
Nov 6, 2008·Journal of Medicinal Chemistry·Mark Seierstad, J Guy Breitenbucher
Jul 18, 2009·International Review of Neurobiology·Silvana GaetaniVincenzo Cuomo
Jan 1, 2008·Current Drug Abuse Reviews·Nadia Solowij, Robert Battisti
Sep 24, 2009·Pharmacology, Biochemistry, and Behavior·M GalizioR C Pitts
Feb 16, 2011·Journal of Addiction Medicine·Rebecca D CreanBarbara J Mason
Apr 1, 2011·British Journal of Pharmacology·Jennifer L Stewart, Lance R McMahon
May 5, 2011·Journal of the Experimental Analysis of Behavior·Brian D KangasMarc N Branch
Jun 7, 2011·Behavioral Neuroscience·Yogita Chudasama
Sep 29, 2011·Frontiers in Behavioral Neuroscience·Claudio ZanettiniSevil Yasar
Jul 14, 2012·Journal of Neuroscience Methods·Brian D Kangas, Jack Bergman
Jun 25, 2013·Animal Cognition·Brian D Kangas, Jack Bergman
Oct 19, 2013·The Proceedings of the Nutrition Society·Roger G Pertwee
Nov 5, 2013·European Journal of Pharmacology·Keith A SharkeyLinda A Parker

❮ Previous
Next ❯

Citations

Jan 7, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William S JohnMichael A Nader
May 8, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·E J Marijke AchterbergLouk J M J Vanderschuren
Oct 25, 2017·Behavioural Pharmacology·Brian D Kangas, Jack Bergman
Apr 11, 2019·Journal of Medical Primatology·Lisa M Wooldridge, Brian D Kangas
Sep 28, 2017·The Journal of Pharmacology and Experimental Therapeutics·Michael Z LeonardBrian D Kangas
Dec 6, 2017·The Journal of Pharmacology and Experimental Therapeutics·William S JohnMichael A Nader
Mar 29, 2019·Current Opinion in Rheumatology·Torsten LowinGeorg Pongratz
Oct 24, 2019·The Journal of Pharmacology and Experimental Therapeutics·Brian D KangasJack Bergman
Feb 27, 2020·Behavioural Pharmacology·Vanessa Minervini, Charles P France
Jan 24, 2020·Behavioural Pharmacology·Michael Z Leonard, Brian D Kangas
May 20, 2020·Expert Opinion on Drug Discovery·Kevin Butler, Bernard Le Foll
Jun 21, 2020·The Journal of Pharmacology and Experimental Therapeutics·Lisa M WooldridgeBrian D Kangas
Oct 5, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shakiru O AlapafujaAlexandros Makriyannis
Jan 29, 2021·The European Journal of Neuroscience·Carol A GianessiJane R Taylor
Mar 21, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Astrid Coronado-ÁlvarezEric Murillo-Rodríguez
Mar 14, 2021·The Journal of Pharmacology and Experimental Therapeutics·Chad R JohnsonJames H Woods
Jul 21, 2021·Life Sciences in Space Research·Rajeev I DesaiCharles L Limoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.

Related Papers

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Zuzana JustinováSteven R Goldberg
Pharmacology, Biochemistry, and Behavior
G E Schulze, M G Paule
© 2021 Meta ULC. All rights reserved